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Summary.-Cell mediated immunocompetence was measured serially in 35 patients
with malignant melanoma in order to determine the effect of extent of disease and
prognosis as well as the influence of BCG immunotherapy on immune reactivity.
Compared with normal adult controls, statistically significant lymphopenia occurred
only in patients with widespread disease. Seventeen of 21 patients with negative
pre-therapy PPD skin test converted to skin test positivity. PHA blastogenesis
was depressed only in patients in the pre-terminal stages of their disease using
optimal mitogen concentrations for stimulation. Threshold concentrations of
this mitogen more clearly demonstrated a depressed responsiveness which corre-
lated in severity with extent of disease. PPD induced blastogenesis was normal or
increased in the majority of patients; however, the degree of stimulation by PPD
was less in the BCG induced convertors than in those patients who were skin test
positive before BCG treatment. Comparison of the pre- and post BCG assessments
reveals no significant differences except in relation to PPD conversion. We conclude
that using threshold concentrations of PHA, impaired responses are regularly
associated with disease beyond the regional lymph nodes. Routine assessment of
lymphocyte function by these parameters did not provide information that was not
available from clinical evaluation.
WHILE it has been known for many
years that advanced cancer is associated
with a failing immune system and, con-
versely, that intact immune competence
is associated with a more favourable
outcome, the observations of Eilber and
Morton in 1970 served to focus attention
again on this subject. Based on these
and other observations, suggesting that
the immune system may play a significant
role in the control of cancer, increasing
numbers of therapeutic programmes have
been devised to stimulate general immuno-
logical reactivity as well as the specific
anti-tumour immune response. The
majority ofpublished reports have utilized
the regular administration of an adjuvant
with or without the addition of tumour
antigens. Despite the considerable acti-
vity in this area, there is still very little
information on the effects of such therapy
on general immunological reactivity as
well as specific anti-tumour responses.
The subject of this report is a sequen-
tial analysis of some parameters of cellular
immunological competence of patients
with recurrent malignant melanoma and
the effect of stage of disease and immuno-
therapy on these parameters.
MATERIALS AND METHODS
Patients-Thirty-six patients with malig-
nant melanoma were referred to the Hamilton
Clinic of the Ontario Cancer Treatment and
Research Foundation for immunotherapy.
Thirty-two of 35 had recurrent disease while
3 had primary lesions. The only criteria for
exclusion were patients with other malig-
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nancies (1 patient with chronic lymphocytic
leukaemia) and patients over 70 years of age.
Most patients were evaluated immunologic-
ally before surgery or immunotherapy if
possible. Surgical excision of local or lymph
nodal recurrences was performed wherever
indicated. No other forms of therapy were
used unless, for palliative purposes, radiation
or chemotherapy was indicated in pre-
terminal patients. Thirty-two normal adult
controls were taken from a pool oflaboratory
and hospital personnel.
Imimunotherapy protocol.-Bacillus Cal-
mette-Guerin (BCG) was obtained from
Connaught Laboratories, Toronto, lyophilized
in 40 mg vials. The equivalent of 5 mg of
freshly reconstituted material was applied to
the surface of one extremity. Six separate
punctures were made through the topically
applied vaccine with a multipronged Heaf
Sterngun fitted with a disposable tip. Vacci-
nation was applied weekly for 4 weeks, every
2 weeks for 8 weeks and then every 4 weeks.
The viability ofthe organisms was confirmed
by bacteriological culture. Three patients
received oneinjection ofautologous irradiated
and neuraminidase treated tumour cells
shortly after surgery. Regular physical
examinations were carried out at the clinic
and routine chest x-rays were performed
every 2 months.
Immunological studies.-Total lympho-
cyte counts were performed monthly as part
of the routine haematological assessment.
Purified protein derivative (PPD, Con-
naught Laboratories, 5TU) skin tests were
performed before starting therapy and at
monthly intervals thereafter. Candida (Hol-
lister-Stier Laboratories, 1: 100) and mumps
(Eli Lilly and Co., 2 u) were administered
before starting therapy and at 3-monthly
intervals thereafter. Initial skin tests were
read by one of us, but subsequently the
patients were instructed in reading their own
skin tests with the aid of a card template.
To confirm the presence of anergy, contact
sensitization with DNCB was performed
(Catalona et al., 1972).
Peripheral blood lymphocytes were cul-
tured without separation using a modification
of the method of Junge et al. (1970). Each
culture consisted of 0-05 ml of heparinized
whole blood in 1-95 ml ofRPMI 1640 without
added antibiotics or serum.
Mitogen responses were assessed by the
addition of phytohaemagglutinin (PHA-P,
Difco) in final concentrations previously
determined to give (a) maximal and (b) thres-
hold stimulation responses in normal sub-
jects. These concentrations varied from
bottle to bottle of PHA and had to be indivi-
dually determined for each lot. A typical
dose response curve based on titrations ofone
lot of PHA with 13 normal donors is shown
in Fig. 1. The concentrations used for
optimal and threshold stimulation would be
10 and 0-3 ,ug/ml respectively. Triplicate
cultures were incubated at 370C in 5%C02
for 67 h, at which time 2 ,uCi of tritiated
thymidine (specific activity 6-7 Ci/mmol)
were added to each culture. After 5 h
further incubation, the cultures were termi-
nated by the addition of 450 ,ug of cold
thymidine and were placed immediately at
-20°C.
Incorporation of radioactive thymidine
was determined by a previously described
method (Dent, 1971), with the modification
that the cell pellet containing intact erythro-
cytes was washed once with 3% acetic acid
and once with normal saline before digestion
with trichloracetic acid.
Proliferative responses to PPD in vitro
were measured with the same technique,
except that cultures were exposed to PPD
(Connaught Laboratories-CT68) for 115 h
before pulsing with tritiated thymidine.
PPD was used at a final concentration of 10
and 1 ,tg/ml.
Statisticalanalysis.-Comparisons between
patient groups and controls were made using
the Student's unpaired t test. To determine
the effect of BCG on the parameters
measured, the pre-BCG response was com-
paredwiththemeanofthepost-BCGresponses
using the paired t test. A P value of <0-05
was considered significant.
RESULTS
Clinical staging
The patients were divided into 4
groups. Group A (83 observations)
included all patients without evidence of
residual disease at the time of testing.
The majority of these patients had had
recurrences which were removed surgi-
cally. Group B (53 observations) included
patients with local recurrences and/or
regional node involvement. Group C
(28 observations) included patients with
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FIG. 1.-Dose response of PHA concentration and 3H-thymidine incorporation
expressed as ct/min (] 1 s.e.).
metastatic disease beyond the regional
lymph nodes. Group D (10 observations)
was a retrospective categorization and
included observations performed in the
6-week preterminal period before the
death of the patient.
Peripheral lymphocyte levels
The normal total circulating lympho-
cyte level was 1906/mm3. In Fig. 2 it
can be seen that there is a progressive
decrease in circulating lymphocyte count
with advancing disease. The lymphocyte
level of patients in Group C is 1346/mm3
which is significantly lower than that of
controls (P < 0.01). There is a slight
rise in preterminal patients (Group D)
but this is not significantly different from
the mean lymphocyte level of patients
in Group C.
Delayed hypersensitivity skin tests
Twenty-one of the 35 patients were
PPD skin test negative at the outset of
BCG immunotherapy and 17/21 converted
to positivity as a result of immuno-
therapy. Following institution of BCG
therapy, 5 patients became skin test
positive to mumps or Candida antigen
after having previously been non-reactive.
Six patients became non-reactive to
Candida or mumpsfollowingBCG therapy.
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FIG. 2.-Absolute peripheral lymphocyte
counts in patients with different stages of
disease. Each point represents the mean
(±1 s.e.) value for each group. The cross
hatched area represents the mean (i 1
s.e.) of normal control values.
As determined by the size ofthe PPD skin
test reaction, no differences could be
detected among Groups A, B and C.
Phytohaemagglutinin stimulation
The in vitro lymphocyte blastogenic
response to optimum stimulating concen-
trations ofPHA are shown in Fig. 3. The
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FIG. 3.-Lymphocyte stimulation with optimal stimulating concentrations of phytohaemagglutinin.
Each point represents the mean (± 1 s.e.) value for each grotup. The cross hatched area represents
the mean (-± I s.e.) of normal control values.
mean (+1 s.d.) response of normal sub-
jects was 52,745 ± 31,334 ct/min. It can
be seen that the mean response of mela-
noma patients was consistently lower than
that of controls and that the decreased
response was proportional to the extent
of disease. However, no statistically sig-
nificant differences were observed in any
group of patients.
Using suboptimal or threshold concen-
trations of PHA, a more striking and
significant depression of responses was
observed (Fig. 4), which was clearly related
to the extent of disease.
The levels of unstimulated thymidinc
incorporation are shown in Fig. 5. Signi-
ficantly depressed levels were seen in
Groups A, C and D, but not in Group B.
PPD stimulation
In our culture system we have deter-
inined (unpublished observations) that
tuberculin sensitivity in vivo in normal
subjects is almost always associated with
a minimum in vitro PPD stimulated
3H-thymidine uptake of2000 ct/min. The
mean (± 1 s.d.) uptake of normal tuber-
culin positive controls in response to
10 ,tg/ml of PPD was 17,168 ± 19,943 ct/
min. The analysis of in vitro PPD
stimulation tests of patients who had
positive in vivo skin tests is shown in
Fig. 6. It can be seen that at 10 ,ug/ml
of PPD, patients in Group B had signifi-
cantly elevated levels ofstimulation, while
at concentrations of 1 jug/ml significantly
increased stimulation was seen in Groups
A, B and C. Most patients in Group D
were anergic and too few results were
obtained for meaningful analysis. Anergy
was, however, associated with very low
levels of 3H-thymidine uptake in response
to PPD.
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FIG. 4.-Lymphocyte stimulation with thres-
hold stimulating concentrations of phyto-
haemagglutinin. Each point represents
the mean (±1 s.e.) value for each group.
The cross hatched area represents the mean
(±1 s.e.) of normal control values.
Effect ofBOG therapy
The effect of BCG therapy on the
immunological parameters studied are
summarized in Fig. 7. The values for
UN'
400
circulating lymphocytes, optimal and
threshold PHA response and in vitro
PPD stimulation before and after therapy
(mean of several estimations) were com-
pared using the paired t test. The PPD
results of pre-therapy skin test negative
and positive patients are examined
separately.
The only significant change occurred
in those patients who converted from
PPD negative to PPD positive. It is
of interest that these patients never
achieved the same degree of hyper-
reactivity which was noted in the patients
who were PPD positive before BCG
therapy. There was a consistent trend
toward decreased reactivity in all other
parameters in the post-BCG state but
these differences did not reach statistical
significance.
DISCUSSION
These studies demonstrate clearly that
with the techniques used, patients with
malignant melanoma can be shown to
develop decreased cell mediated immune
reactions with increasing tumour burdens.
The level of sensitivity of most of the
parameters is such that significantly
impaired responses are detected only in
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FIG. 5.-Unstimulated 3H-thymidine incorporation. Each point represents the mean (±1 s.e.)
value for each group. The cross hatched area represents the mean (+1 s.e.) of normal control
values.
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FIG. 6.-Lymphocyte stimulation with 10 ,ug/ml (left) and 1 pg/ml (right) of purified protein deriva-
tive. Each point represents the mean (+1 s.e.) value for each group. The cross hatched area
represents the mean (± i s.e.) of normal control values.
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FIG. 7.-Effect of BCG immunotherapy on absolute peripheral lymphocyte counts, phytohaemag-
glutinin stimulation and PPD stimulation. Patients who were PPD positive before beginning
therapy are analysed separately from those who were PPD negative. PRE refers to pre-therapy
values; POST refers to mean of values obtained while on therapy. Statistical analysis was per-
formed bv the paired Students' t test comparing PRE- and POST values.
pre-terminal patients. Only when thres-
hold concentrations of PHA are used can
impaired responses in patients with less
advanced disease be demonstrated. The
importance of using suboptimal mitogen
concentrations in demonstrating quanti-
tative reductions in PHA reactivity has
been reported previously (Oppenheim,
Blaese and Waldman, 1970; Hosking,
Fitzgerald and Simons, 1971; Faguet,
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Balcerzak and LoBuglio, 1973; Finkel and
Dent, 1973). The mechanism of impaired
reactivity to threshold PHA concentra-
tions is not clear but it has been suggested
that the response to threshold concentra-
tions of PHA is dependent on macro-
phages (Oppenheim, Leventhal and Hersh,
1968). It may be, therefore, that the
impaired threshold response noted in
these studies reflects an abnormality of
macrophages rather than lymphocytes, a
finding in keeping with the recent report
of abnormal monocyte chemotaxis in
patients with cancer (Boetcher and
Leonard, 1974). Further studies are
required to determine if defective mono-
cyte chemotaxis and impaired threshold
PHA responses are directly related.
Previous studies of cell mediated
immunity have not revealed any consis-
tent defects in patients with malignant
melanoma. Ziegler et al. (1969) found no
impairment of response to skin tests,
DNCB sensitization or PHA response
in vitro. Siegler et al. (1973), in a more
intensive study of patients with more far
advanced disease, found a decrease in
delayed hypersensitivity skin test reac-
tivity. In vitro stimulation tests with
PHA failed to reveal any abnormalities.
Catalona and Chretien (1973) reported
that 69% of patients with melanoma had
impaired DNCB reactivity; 25% of these
were totally anergic. There was no
difference in the frequency of impairment
amongpatientswithlocalizedormetastatic
disease. Catalona, Sample and Chretien
(1973) found no impairment of PHA
reactivity in 17 patients with melanoma.
For unexplained reasons, if patients with
localized disease were analysed separately,
abnormally low responses were seen com-
pared with patients with widespread
disease. Finally, in contrast to the results
of Catalona et al. (1973), Golub, O'Connell
and Morton (1974) reported that patients
with melanoma as a group have a signifi-
cantly depressed response to mitogen
stimulation with a much lower rate of
anergy to DNCB sensitization (180 %).
Their findings resemble more closely those
which we have presented in this report.
The effect ofBCG therapy on immuno-
logical reactivity is a subject of great
importance since, apart from survival or
measurable disease regression, it is another
parameter by which to gauge the possible
effectiveness of this form of therapy.
Bluming et al. (1972) have reported that
BCG therapy by dermal scarification had
anonspecificpotentiatingeffectondevelop-
ment of contact sensitivity to picryl
chloride and on the recall of skin test
reactivity to other skin test antigens
which was not seen when lower doses of
BCG were given by intradermal inocula-
tion. No change in peripheral lympho-
cyte levels was noted. Chess et al. (1973)
reported an increase in in vitro responses
to recall antigens but no increase in PHA
or mixed leucocyte reactivity. Gutter-
man et al. (1973) reported an increase in
size of existing skin test reaction sites as
well as some conversions from negative
to positive responses to recall antigens
but no effect on in vitro responses to PHA
or specific antigens, or on circulating
lymphocyte levels. Sokal, Aungst and
Han (1973) also reported an increase in
skin test reactivity to recall antigens in
patients with various forms of lymphoma
treated with BCG. Our studies confirm
the above findings relative to mitogen
responses and lymphocyte levels. We
did not carefully examine the response to
recall antigens although 4 patients did
show positive Candida or mumps res-
ponses following BCG therapy after having
been skin test negative to these antigens
before BCG administration.
At the time of writing, 15 of the 35
patients have died. Analysis of the data
to determine if those patients who have
died had initially lower responses failed to
reveal any significant differences when
compared with the initial values for those
patients who are still alive. Impaired
responses were more directly related to
the extent of disease. At the frequency
with which the tests were performed, we
were unable to attach any predictive
value to falling immune competence as
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such changes almostalwayswereassociated
with clinical evidence of progressioni.
Finally, while we have shown that the
extent of disease does correlate with a
number of parameters of host responses,
we donotfeelthattheinformationobtained
is of any assistance in the management of
the patient with cancer. As yet, there is
little evidence that any form of immuno-
therapy produces a quantifiable effect on
general immune competence that corre-
lates with patient survival. While it is of
interest, though not universally true
(Chakravorty etal., 1973; Greene, Schimpff
and Wernik, 1974), that intact immune
reactivity correlates with good prognosis
(Harris and Copeland, 1974), this know-
ledge does little to help the clinician in
making management decisions about ind-
ividual patients. Untilweareableregularly
and predictably to influence immuno-
competence of cancer patients, the routine
and widespread performance of tests of
nonspecific immunocompetence should be
discouraged.
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